Wall Street brokerages expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $193.54 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Myriad Genetics’ earnings. The lowest sales estimate is $193.00 million and the highest is $194.28 million. Myriad Genetics reported sales of $186.50 million during the same quarter last year, which indicates a positive year over year growth rate of 3.8%. The business is expected to announce its next earnings report on Tuesday, August 8th.

According to Zacks, analysts expect that Myriad Genetics will report full year sales of $193.54 million for the current fiscal year, with estimates ranging from $764.00 million to $768.13 million. For the next fiscal year, analysts forecast that the business will report sales of $791.18 million per share, with estimates ranging from $770.91 million to $848.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that cover Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The firm had revenue of $196.90 million during the quarter, compared to analysts’ expectations of $188.89 million.

Several brokerages recently issued reports on MYGN. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $22.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Finally, Deutsche Bank AG lifted their price objective on Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a report on Monday, May 8th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. Myriad Genetics presently has an average rating of “Hold” and a consensus target price of $22.00.

Shares of Myriad Genetics (NASDAQ:MYGN) opened at 23.86 on Wednesday. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $32.54. The stock has a market capitalization of $1.63 billion, a PE ratio of 50.98 and a beta of 0.32. The company’s 50 day moving average price is $24.48 and its 200 day moving average price is $20.14.

TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/26/myriad-genetics-inc-mygn-expected-to-announce-quarterly-sales-of-193-54-million.html.

Institutional investors have recently added to or reduced their stakes in the company. Parametrica Management Ltd bought a new position in Myriad Genetics during the first quarter worth $236,000. Capstone Asset Management Co. bought a new position in Myriad Genetics during the first quarter worth $336,000. Bank of Montreal Can boosted its position in Myriad Genetics by 5.2% in the first quarter. Bank of Montreal Can now owns 112,150 shares of the company’s stock worth $2,154,000 after buying an additional 5,529 shares during the period. Creative Planning boosted its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock worth $122,000 after buying an additional 671 shares during the period. Finally, Foundry Partners LLC boosted its position in Myriad Genetics by 3.6% in the first quarter. Foundry Partners LLC now owns 22,500 shares of the company’s stock worth $432,000 after buying an additional 775 shares during the period.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.